Cancer Vaccines
"Identification of Class II-Restricted Melanoma Antigen in a Long-Lived Patient with Melanoma: Implication in Terms of Vaccine Strategies."
Published in Vaccine Weekly, September 20th, 1999
According to an abstract submitted by the authors to the 60th Annual Meeting of the Society for Investigative Dermatology, held May 5-9, 1999, in Chicago, Illinois, "Many MHC Class I melanoma antigens recognized by CD8+ T cells have been reported but few MHC Class II-restricted epitopes recognized by CD4+ T cells have been so far identified. These epitopes are of critical interest given recent reports suggesting that CD8+ CTL activity is observed in vivo only in the presence of CD4+ T-cell help. Here we have studied CD8+ T- and CD4+ T-cell responses against autologous melanoma in a long-lived patient with visceral...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1999-09-20)
More Articles from Vaccine Weekly
- Conference Coverage (IHV)
Epitopes Sought for Fusion-Competent HIV Vaccine - Conference Coverage (IHV)
HIV Fusion Dissected - Pathogenesis
Nef: HIV's Siren Lures T Cells to their Doom - Cancer Immunogene Therapy
Tumor-Targeted IL-2 Amplifies Immune Response - HBV Vaccine (Alternative Therapies)
Herbal Medicine Shows Anti-HBV Synergy with Vaccine - Breast Cancer (Clinical Trials)
Immunotherapy Trial Initiation Announced - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
